If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00354653","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Non-randomized","arm_groups":[],"assignment":"Single Group Assignment","brief_summary":"The efficacy of lamivudine in Hepatitis Be Antigen (HBeAg) positive Asian patients of chronic hepatitis has been well established.The evidence in HBeAg negative patients is limited. Limited sustained response was observed post-treatment following a one year treatment period. Whether these results can be applied to patients in Iran is uncertain. This study is therefore intended to further assess the efficacy profile after two years of open treatment in the adult Iranian population.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B alone","conditions":[{"DisplayValue":"Hepatitis B","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_B","LookupValue":"Chronic Hepatitis B","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:02:47","criteria":"Inclusion Criteria: - Confirmed active liver disease due to Hepatitis B virus. - Patients must have adequate blood & liver functions. - Female patients of child-bearing potential must be non pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control. - Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible. Exclusion Criteria: - Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or taking alcohol will not be eligible.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Unmapped","display_status_internal":"RECSTATUS_UNMAPPED","endpoint":"","enrollment":"100","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"no","id":"8fe6544c-97c3-51d1-aea4-e7c84ce355c1","internal":{"content":null,"contentDigest":"fcdf781f0b0c3dfa4b55e289a933abed","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Confirmed active liver disease due to Hepatitis B virus. - Patients must have adequate blood & liver functions. - Female patients of child-bearing potential must be non pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control. - Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible. Exclusion Criteria: - Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or taking alcohol will not be eligible.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"LAMIVUDINE","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":false,"keywords":["HBeAg","HBV","CHRONIC HEPATITIS","lamivudine"],"last_follow_up_date":null,"links":[],"locations":[{"City":"Tehran","Latitude":"35.6891975","CountryDisplay":"Iran","Longitude":"51.3889736","Name":"GSK Clinical Trials Call Center","StateDisplay":"N/A","PostalCode":"1919954186","StatusDisplay":"No longer recruiting","StatusDisplayInternal":"LOCSTATUS_NO_LONG_REC","StatusMapped":"Recruitment Complete"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"15","minimum_age_raw":"15 Years","modified_date":"10/01/2018 23:07:34","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (presumed pre-core mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.","org_study_id":"NUC 30956","overall_contact":{"email":null,"last_name":null,"phone":null},"overall_status":"No longer recruiting","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"4","primary_compl_date":null,"primary_outcomes":[{"outcome_description":"","outcome_measure":"Complete virologic response at Month 24 which is normalisation of alanine aminotransferase (ALT) and disappearance of HBV DNA by NAXCOR(brand name of a virus assay kit)","outcome_time_frame":"","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"NA","id_type":"","id_domain":""}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Partial response, histological improvement (at 24 months). Sustained complete response, sustained partial response at 30 months.","outcome_time_frame":"","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["None"]},"start_date":"02/01/2002 00:00:00","study_type":"interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"","is_results_ref":"None","pubmed_id":""}],"is_section_801":null}},"pageContext":{"studyId":"NUC 30956"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}